<?xml version='1.0' encoding='utf-8'?>
<document id="25102375"><sentence text="A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer."><entity charOffset="19-31" id="DDI-PubMed.25102375.s1.e0" text="cabozantinib" /><entity charOffset="33-38" id="DDI-PubMed.25102375.s1.e1" text="XL184" /><pair ddi="false" e1="DDI-PubMed.25102375.s1.e0" e2="DDI-PubMed.25102375.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25102375.s1.e0" e2="DDI-PubMed.25102375.s1.e1" /></sentence><sentence text="Cabozantinib targets tyrosine kinases including MET, vascular endothelial growth factor (VEGF) receptor 2, and rearranged during transfection (RET)"><entity charOffset="0-12" id="DDI-PubMed.25102375.s2.e0" text="Cabozantinib" /><entity charOffset="21-29" id="DDI-PubMed.25102375.s2.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.25102375.s2.e0" e2="DDI-PubMed.25102375.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25102375.s2.e0" e2="DDI-PubMed.25102375.s2.e1" /></sentence><sentence text=" Differentiated thyroid cancer (DTC) is a tumor type that may be sensitive to cabozantinib"><entity charOffset="78-90" id="DDI-PubMed.25102375.s3.e0" text="cabozantinib" /></sentence><sentence text=" Therefore, we evaluated cabozantinib in a cohort of heavily pretreated patients with metastatic DTC"><entity charOffset="25-37" id="DDI-PubMed.25102375.s4.e0" text="cabozantinib" /></sentence><sentence text="" /><sentence text="This single-arm open-label phase I trial assessed the safety, tolerability, and antitumor activity of cabozantinib in DTC patients taking part in a drug-drug interaction study"><entity charOffset="102-114" id="DDI-PubMed.25102375.s6.e0" text="cabozantinib" /></sentence><sentence text=" Adult patients with histologically confirmed metastatic or surgically unresectable DTC (including papillary, follicular, or Hürthle cell) were enrolled" /><sentence text=" Patients received daily oral dosing of 140 mg cabozantinib"><entity charOffset="47-59" id="DDI-PubMed.25102375.s8.e0" text="cabozantinib" /></sentence><sentence text=" Safety was assessed by evaluation of adverse events (AEs), vital signs, electrocardiograms, laboratory tests, and concomitant medications" /><sentence text=" Tumor response by magnetic resonance imaging or computed tomography scan was investigator assessed using Response Evaluation Criteria In Solid Tumors (RECIST) v1" /><sentence text="0" /><sentence text="" /><sentence text="The study enrolled 15 patients who had failed standard radioactive iodine therapy"><entity charOffset="67-73" id="DDI-PubMed.25102375.s13.e0" text="iodine" /></sentence><sentence text=" Patients had received a median of two prior systemic agents, and 11 patients (73%) had previously received at least one VEGF pathway inhibiting therapy" /><sentence text=" Common AEs included diarrhea, nausea, fatigue, and decreased appetite" /><sentence text=" Partial response was reported in eight patients (53%)" /><sentence text=" Median progression-free survival and median overall survival were not reached" /><sentence text="" /><sentence text="Cabozantinib demonstrates a safety profile similar to other multitargeted VEGFR inhibitors in advanced DTC patients"><entity charOffset="0-12" id="DDI-PubMed.25102375.s19.e0" text="Cabozantinib" /></sentence><sentence text=" The antitumor activity observed in this study warrants further investigation of cabozantinib in patients with advanced DTC"><entity charOffset="81-93" id="DDI-PubMed.25102375.s20.e0" text="cabozantinib" /></sentence><sentence text="" /></document>